190 related articles for article (PubMed ID: 14959510)
21. [Hereditary breast cancer: treatment and prevention].
Ejlertsen B; Gerdes AM
Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
23. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
25. Mutational spectrum of p53 mutations in primary breast and ovarian tumors.
Feki A; Irminger-Finger I
Crit Rev Oncol Hematol; 2004 Nov; 52(2):103-16. PubMed ID: 15501075
[TBL] [Abstract][Full Text] [Related]
26. [Familial breast cancer, ovarian cancer].
Inoue M
Nihon Rinsho; 2006 Jun; Suppl 2():366-70. PubMed ID: 16817423
[No Abstract] [Full Text] [Related]
27. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes.
Nusbaum R; Vogel KJ; Ready K
Breast Dis; 2006-2007; 27():21-50. PubMed ID: 17917139
[TBL] [Abstract][Full Text] [Related]
28. Hereditary breast cancer.
Robson ME; Boyd J; Borgen PI; Cody HS
Curr Probl Surg; 2001 Jun; 38(6):387-480. PubMed ID: 11375625
[No Abstract] [Full Text] [Related]
29. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
30. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
[TBL] [Abstract][Full Text] [Related]
32. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
33. Hereditary ovarian cancer--assessing risk and prevention strategies.
Pavelka JC; Li AJ; Karlan BY
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):651-65, vii-viii. PubMed ID: 18061862
[TBL] [Abstract][Full Text] [Related]
34. Inherited susceptibility to breast cancer.
Easton D; Ford D; Peto J
Cancer Surv; 1993; 18():95-113. PubMed ID: 8013003
[TBL] [Abstract][Full Text] [Related]
35. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
36. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
37. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
[TBL] [Abstract][Full Text] [Related]
38. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
39. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
[TBL] [Abstract][Full Text] [Related]
40. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]